Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UN Panel Report: Positions Still Polarized Over Medicines Access Barriers

Executive Summary

The report by the independent panel shows that the companies that develop and produce medicines, and the non-governmental organizations working on health issues at local level, still disagree fundamentally on the best way to go about improving access to those medicines. While R&D firms are skeptical of the report’s recommendations, the feeling among NGOs seems to be that this report represents something of a landmark development in the access debate.


Related Content

$1–2 Per Month Could Help Solve Access To Essential Medicines Problem, Experts Say
MEPs Slate EU Industry Practices In Report On Barriers To Medicines Access
Will UN Report On Access To Medicines Change Anything?
'Skyrocketing' Drug Prices, Access And Availability In Line For EU Scrutiny